Most Read Articles
12 Jun 2019
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
2 days ago
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 13 Jun 2019

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

13 Jun 2019
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Market Watch - QV Intensive with Ceramides

01 Sep 2018

QV Intensive with Ceramides
Ego Pharm Malaysia Sdn Bhd

A scientific approach to eczematous skin:

·Unique formulation with combination of ceramides, lactic acid and niacinamide.
·QV Intensive with Ceramides unique dual action helps to restore epidermal barrier function.
·Delivers ceramides (EOP and NP), cholesterol and free fatty acids in the optimum 3:1:1 molar ratio which has been shown to help support and replenish the epidermal barrier.1
·Provides lactic acid and niacinamide, which have been shown to help support synthesis of ceramides from within.2,3
·Increases skin hydration and reduces transepidermal water loss (TEWL).4
·Rehydrates and soothes dry, itchy or damaged skin.4
·Free of preservatives, soap, fragrance and allergens which ensures suitability for patients with eczematous skin.
·Non comedogenic.
·Pediatrician tested.
·Dermatologically and ophthalmologically tested.
·Part of Ego Pharm’s integrated range to help prevent and manage mild-to-moderate eczema.
·Proud Gold Supporter of Eczema Association of Australasia.

Clinical study for QV Intensive with Ceramides
·QV Intensive with Ceramides Cream provide 110% more hydration as compared to similar brands in the market.4 (Figure 1)

Figure 1_QV Intensive with Ceramides

·Reduction in TEWL was observed over 5 days following topical application of QV Intensive with Ceramides Light Moisturising Cream.4 (Figure 2)
Figure 2_QV Intensive with Ceramides

Importance of the 3:1:1 ceramide dominant molar ratio
Ceramides, cholesterol and fatty acids are the predominant lipids in the stratum corneum or skin barrier.2,3 Ceramides must be delivered in the correct ratio with cholesterol and free fatty acids in order for ceramide-containing products to have a positive effect on the barrier function.5 The optimal molar ratio is 3:1:1, with ceramides being the dominant component.3

In order for topical ceramide products to be effective, a correct relative molar ratio of ceramides, cholesterol and fatty acids must be formulated into the right delivery system. Hence, knowledge of skin is as important as knowledge of formulation science. New QV Intensive with Ceramides products have unique formulations which have been designed to ensure delivery of ceramide, cholesterol and fatty acids in an optimal ratio.

References: 1. Rawlings AV, Maibach HI. Advances in Dry Skin Stratum Corneum Biology and Moisturization. In: Maibach HI, ed. A Dermatological View: from Physiology to Therapy. Illinois: Allured books; 2011: 367–380. 2. Rawlings AV, et al. Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. Arch Dermatol Res. 1996;288:383–390. 3. Tanno O, et al. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol. 2000;143:524–531. 4. Data on file; Spada, F, Greive KA and Barnes TM, 2018. In preparation. 5. Chamlin SL, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002:47(2);198–208.

 

 


Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2019
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
2 days ago
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 13 Jun 2019

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

13 Jun 2019
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.